Description

ARA-290 50mg × 10 vials

A synthetic EPO-derived peptide studied for tissue-protection research, innate repair receptor pathways, neuropathy-related models, inflammatory response modulation, pain-signaling mechanisms, metabolic dysfunction research, and broader cellular repair protocols.

Product Overview

Compound: ARA-290 / Cibinetide
Strength: 50 mg per vial
Injection type: Research protocol dependent
Frequency: Research protocol dependent

Reconstitution

Amount in vial: 50 mg
BAC water: 2 mL
Amount per unit: 250 mcg per unit

Research Dose

Protocol dependent.

Notes

ARA-290, also known as Cibinetide, is described as a synthetic peptide derived from the tissue-protective region of erythropoietin. It is studied for activity related to the innate repair receptor, which is associated with tissue protection, inflammatory response modulation, and cellular repair pathways.

Research literature has examined ARA-290 in relation to small-fiber neuropathy models, neuropathic pain pathways, autoimmune-related inflammation, metabolic dysfunction research, endothelial function, and tissue-repair signaling.

Unlike erythropoietin, ARA-290 is studied as a non-erythropoietic peptide, meaning it is not primarily researched for red blood cell production.

Most available evidence comes from laboratory, animal, and clinical research contexts. No standard consumer dosing protocol should be assumed.

Use only within appropriate research or professional guidance frameworks.